Houdini Bio
Develops gene therapy technologies aimed at tackling DNA silencing, a barrier that can limit durable therapeutic expression.
Overview
Houdini Bio is a biotechnology company developing approaches to address DNA silencing in gene therapies. Its work targets a core durability challenge for therapeutic developers seeking sustained gene expression. The company emerged from stealth with a €1.7 million pre-seed round, reported as about $2 million in total funding. The financing positions Houdini Bio at an early stage as it advances technology focused on improving gene therapy performance.
Funding History
Houdini Bio emerges from stealth with €1.7 million to tackle DNA silencing in gene therapies
Frequently Asked Questions
- How much has Houdini Bio raised in total?
- Houdini Bio has raised a total of $2M across 1 funding round.
- Who are Houdini Bio's investors?
- Houdini Bio's investors include Undisclosed.
- What does Houdini Bio do?
- Houdini Bio is a biotechnology company developing approaches to address DNA silencing in gene therapies. Its work targets a core durability challenge for therapeutic developers seeking sustained gene expression. The company emerged from stealth with a €1.7 million pre-seed round, reported as about $2 million in total funding. The financing positions Houdini Bio at an early stage as it advances technology focused on improving gene therapy performance.
- Where is Houdini Bio headquartered?
- Houdini Bio is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track every AI funding round in 2026—fintech, infrastructure, enterprise deals & valuations. Updated daily with May/June rounds, top VCs, and startup trends.